

A-TCRN | A-T Clinical Research Network

Programme for A-TCRC Zoom

Therapeutic Interventions for A-T: Part 2

Wed, Feb 2nd at 7AM PT / 10AM EST / 3 pm UK / 4 pm EU

In this meeting, we will cover two further potential therapeutic interventions for A-T. We will also discuss the design of clinical trials for rare diseases like A-T and finally initiate a discussion about biomarkers to help clinical trial evaluation.

10.00 AM EST: Welcome and introductions by Cynthia Rothblum-Oviatt

10.05: David Coman: Triheptanoin - A trial in progress for A-T (recorded presentation)

10.20: Discussion (note this will not be Q&A style)

10.30: David Lynch: Omaveloxolone - Presentation of findings with Friedreich's ataxia and insights on clinical trial design for rare diseases

10.55 Q&A and Discussion

11.10: Helena Donath: Potential biomarkers for A-T – NF-L and miRNA

11.25: Q&A and Discussion

11.35: Howard Lederman: Finding biomarkers for A-T – potential for an in-depth session

11.50: General discussion - Biomarkers

12.00: Last minute Q&A / Discussion for all speakers

12.30: Adjourn



Thank you to the UK A-T Society for their support of the A-TCRC Zoom Sessions